Cantor Fitzgerald raises Humana price target to $300
Cantor Fitzgerald analyst Sarah James maintains a Neutral rating on Humana (NYSE: HUM) and raises the price target to $300 from $264, reflecting a revised valuation outlook.

*this image is generated using AI for illustrative purposes only.
Cantor Fitzgerald analyst Sarah James has maintained a Neutral rating on Humana (NYSE: HUM) while raising the price target to $300 from $264. The revised target indicates a higher valuation expectation despite the unchanged stance on the stock's performance potential.
The decision to increase the price target suggests an updated assessment of Humana's financial position or market conditions. However, the Neutral rating implies that the analyst does not see sufficient catalysts for a Buy recommendation at this time.
The following table outlines the revised rating details:
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $264 |
| New Price Target | $300 |
Investors will monitor Humana's upcoming earnings reports and strategic developments for further clarity on the company's trajectory. The current rating balances the raised price target with a cautious outlook on near-term growth drivers.
What specific factors could shift Humana's rating from Neutral to Buy in the coming quarters?
How might changes in Medicare Advantage reimbursement rates impact Humana's future profitability?
What strategic developments is Humana pursuing to drive growth beyond its current valuation?































